Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV140 sublingual bacterial vaccine versus placebo for prevention of recurrent urinary tract infections in women
2013-001838-17Phase 3Active
- Sponsor
- Inmunotek
- Start
- Feb 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MV140 in urinary tract infection (UTI) (3 arms), sponsored by Inmunotek. Primary endpoint: Average of diagnosed or symptomatic episodes of urinary tract infection during study time. Started Feb 2015; status: active.
02
Drugs
MV140
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2013-001838-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001838-17.